Distinguished in Prostate Cancer

Dr. Theodore L. Deweese

Radiation Oncology
600 N Wolfe St, 
Baltimore, MD 
Accepting New Patients
Distinguished in Prostate Cancer
600 N Wolfe St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Theodore Deweese is a Radiation Oncologist in Baltimore, Maryland. Dr. Deweese is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Prostatectomy, and Orchiectomy. Dr. Deweese is currently accepting new patients.

His clinical research consists of co-authoring 145 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 81 articles and participated in 7 clinical trials in the study of Prostate Cancer.

Specialties
Radiation Oncology
Licenses
Radiology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

600 N Wolfe St, Baltimore, MD 21287

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
Non-invasive Detection of Cancer DNA in Blood and Urine
Non-invasive Detection of Cancer DNA in Blood and Urine
Enrollment Status: Active_not_recruiting
Publish Date: July 04, 2025
Intervention Type: Procedure
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: DCFPyL
Study Phase: Early Phase 1
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2025
Intervention Type: Other, Drug
Study Drug: Flutamide
Study Phase: Early Phase 1
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Drug: Radium-223
Study Phase: Phase 2
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate
Enrollment Status: Active_not_recruiting
Publish Date: June 07, 2024
Intervention Type: Drug, Radiation
Study Drug: Androgen deprivation therapy 
Study Phase: Phase 1/Phase 2
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2024
Intervention Type: Radiation
Study Phase: Phase 2
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Enrollment Status: Unknown
Publish Date: May 31, 2023
Intervention Type: Drug, Radiation
Study Drug: Enzalutamide
Study Phase: Phase 2
View 7 Less Clinical Trials

145 Total Publications

Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer.
Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer.
Journal: bioRxiv : the preprint server for biology
Published: June 04, 2025
Similar Doctors
Elite in Prostate Cancer
Dr. Phuoc T. Tran
Radiation Oncology
Elite in Prostate Cancer
Dr. Phuoc T. Tran
Radiation Oncology

Maryland Proton Treatment Center, LLC

850 W Baltimore St, 
Baltimore, MD 
 (2.2 miles away)
410-227-7434
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Phuoc Tran is a Radiation Oncologist in Baltimore, Maryland. Dr. Tran is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Lung Cancer, Prostatectomy, and Pancreaticoduodenectomy. Dr. Tran is currently accepting new patients.

Elite in Prostate Cancer
Dr. Anatoly Dritschilo
Radiation Oncology
Elite in Prostate Cancer
Dr. Anatoly Dritschilo
Radiation Oncology
3800 Reservoir Rd Nw, 
Washington, DC 
 (37.2 miles away)
202-444-3320
Languages Spoken:
English
See accepted insurances

Anatoly Dritschilo is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Dritschilo is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Liver Embolization.

Elite in Prostate Cancer
Dr. Curtiland J. Deville
Radiation Oncology
Elite in Prostate Cancer
Dr. Curtiland J. Deville
Radiation Oncology

Johns Hopkins University

5215 Loughboro Rd Nw, Sibley Memorial Hospital, 
Washington, DC 
 (37.2 miles away)
202-537-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Curtiland Deville is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Deville is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Myxoid Liposarcoma, Liposarcoma, and Prostatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Deweese's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile